drugset
drugset / Trial / NCT03346122

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

NCT03346122 ↗

Phase 1 Completed 86 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to evaluate safety and tolerability of JNJ-64991524 compared with placebo after administration of single ascending oral doses of JNJ-64991524 (Part 1) and multiple ascending oral doses of JNJ-64991524 (Part 2) in healthy participants.

Timeline

Start
2017-11-15
Primary completion
2018-11-20
Completion
2018-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64991524 Unknown — Oral

Indications

No indication recorded.